← Back to headlines
Altimmune rises as GLP-1 cuts drinking in mid-stage trial
Altimmune's stock increased following positive results from its mid-stage trial for a GLP-1 drug, which showed a reduction in alcohol consumption.
28 Jul, 11:29 — 28 Jul, 11:29
Sources
Showing 1 of 1 sources
